Yungamycin A has been demonstrated to have unexpected in vivo anticancer activity. New compounds Yungamycin B and C are also disclosed, and have been demonstrated to be specific for DT-diaphorase, as well as to have in vivo anticancer activity.

 
Web www.patentalert.com

< Method and compositions for temporarily incapacitating subjects

< L-ascorbic acid and pectin composition

> Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors

> 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
~ 00239